Market-Moving News for June 4th
$ANNX
$AX
$VKTX
Biotechnology: Pharmaceutical Preparations
Health Care
Savings Institutions
Finance
Save time and jump to the most important pieces.
| Company | Date | Price Target | Rating | Analyst |
|---|---|---|---|---|
| 11/4/2024 | $90.00 → $102.00 | Buy | H.C. Wainwright | |
| 10/11/2024 | $82.00 | Buy | Needham | |
| 9/11/2024 | $80.00 | Overweight | JP Morgan | |
| 7/31/2024 | $79.00 | Outperform → Mkt Perform | Keefe Bruyette | |
| 6/27/2024 | $105.00 | Overweight | Morgan Stanley | |
| 5/16/2024 | $115.00 → $116.00 | Outperform → Strong Buy | Raymond James | |
| 3/26/2024 | $116.00 → $138.00 | Outperform | Oppenheimer | |
| 3/7/2024 | $110.00 | Buy | Jefferies |
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Up to 6.8% Placebo-Adjusted Mean Weight Loss (8.2% from Baseline) After 28 Days of Dosing with Oral Tablet of VK2735 Encouraging Tolerability Through 100 mg Daily Dosing with Oral VK2735; Mild GI-Related Adverse Event Profile Updated Results from VENTURE Phase 2 Study of Subcutaneous VK2735 Show Durable Effects and Support Potential Monthly Dosing Regimen SAN DIEGO, Nov. 4, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that new clinical data from the company's VK2735 obesity program were highlighted in two poster present
The partnership will enhance client service and streamline operations for hybrid firms and their advisors Axos Clearing, a subsidiary of Axos Financial Inc. (NYSE:AX) and a leading clearing firm that combines innovative technology with personalized service, today announced a strategic partnership with Envestnet, a provider of integrated technology, data intelligence, and wealth solutions. The partnership will integrate Envestnet's managed account solutions into Axos Clearing's Axos Complete portal, empowering hybrid broker-dealers (BDs) and registered investment advisers (RIAs) to enhance client service and streamline operations. "Partnering with Envestnet to integrate their managed accou
4 - Axos Financial, Inc. (0001299709) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Viking Therapeutics, Inc. (0001607678) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
4 - Annexon, Inc. (0001528115) (Issuer)
8-K - Axos Financial, Inc. (0001299709) (Filer)
8-K - Viking Therapeutics, Inc. (0001607678) (Filer)
10-Q - Axos Financial, Inc. (0001299709) (Filer)
H.C. Wainwright reiterated coverage of Viking Therapeutics with a rating of Buy and set a new price target of $102.00 from $90.00 previously
Needham initiated coverage of Axos Financial with a rating of Buy and set a new price target of $82.00
JP Morgan initiated coverage of Viking Therapeutics with a rating of Overweight and set a new price target of $80.00
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
SC 13G/A - Viking Therapeutics, Inc. (0001607678) (Subject)
BRISBANE, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Annexon, Inc. (NASDAQ:ANNX), a biopharmaceutical company advancing novel complement therapies for neuroinflammatory diseases of the body, brain, and eye, today announced the strengthening of its senior leadership team with the appointment of Shikhar Agarwal, M.B.A. as senior vice president, head of commercial, Sunil B. Mehta, Pharm.D as senior vice president of medical affairs and Myoung Kim, PHD, M.A., M.B.A. as vice president of health economics and outcomes research. "We are excited to welcome Shikhar, Sunil and Myoung to the Annexon family as we prepare for commercial development of our flagship programs in Guillain-Barré Syndrome (
SAN DIEGO, April 16, 2024 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. ("Turnstone" or the "Company") (NASDAQ:TSBX), a clinical-stage biotechnology company developing a differentiated approach to treat and cure patients with solid tumors by pioneering selected tumor-infiltrating lymphocyte (Selected TIL) therapy, today announced the appointment of industry veteran William Waddill to the Company's Board of Directors. The Company also announced that Patrick Machado has stepped down as a member of its Board of Directors. These changes became effective as of April 15, 2024. "I am pleased to welcome Will to our Board of Directors at this exciting time for Turnstone," said Sammy Farah, M.B.A.,
Axos Financial, Inc. (NYSE:AX) ("Axos" or the "Company") announces the election of Sara Wardell-Smith as an independent director of the Board of Directors of the Company and the Board of Directors of Axos Bank, effective December 1, 2023. Ms. Wardell-Smith has extensive experience in wholesale banking, global payments, fintech partnerships and board service. "On Axos' behalf, I would like to extend a warm welcome to Sara," said Paul Grinberg, Chairman of the Board of Directors. "Sara's leadership and expertise from her experience at global leaders such as Visa and Wells Fargo will be highly additive as Axos prepares for its next decade of growth." Ms. Wardell-Smith is the former head of
HC Wainwright & Co. analyst Joseph Pantginis reiterates Viking Therapeutics (NASDAQ:VKTX) with a Buy and maintains $90 price target.
Shares of Indivior PLC (NASDAQ:INDV) rose sharply in today's pre-market trading after the company posted better-than-expected second-quarter results and announced an accelerated $100 million share repurchase program. Indivior reported quarterly earnings of 44 cents per share which beat the analyst consensus estimate of 14 cents per share. The company reported quarterly sales of $299.00 million which beat the analyst consensus estimate of $296.05 million. Indivior shares jumped 14.5% to $12.46 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Psyence Biomedical Ltd. (NASDAQ:PBM) rose 157.4% to $1.00 in pre-market trading after the company
Third quarter performance driven by strong portfolio royalty revenue growth 2024 full year revenue guidance increased to $160 million - $165 million (previously $140 million - $157 million) and core adjusted earnings per diluted share1 increased to $5.50 - $5.70 (previously $5.00 - $5.50) Company to hold Investor and Analyst Day in Boston on December 10, 2024 Conference call begins at 8:30 a.m. Eastern Time today Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three and nine months ended September 30, 2024, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Easter
Axos Financial, Inc. (NYSE:AX) ("Axos" or the "Company") today announced unaudited financial results for the first fiscal quarter ended September 30, 2024. Net income was $112.3 million, an increase of 35.9% from $82.6 million for the quarter ended September 30, 2023. Diluted earnings per share ("EPS") were $1.93, an increase of $0.55, or 39.9%, as compared to diluted earnings per share of $1.38 for the quarter ended September 30, 2023. Adjusted earnings and adjusted earnings per diluted common share ("Adjusted EPS"), non-GAAP measures described further below, increased $29.5 million to $114.1 million and increased $0.55 to $1.96, respectively, for the quarter ended September 30, 2024, com
Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24Results of Phase 2b VOYAGE Study of VK2809 in NASH/MASH With Fibrosis Selected for Oral Presentation at AASLDPositive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma LipidsStrong Quarter-End Cash Position of $930 MillionSAN DIEGO, Oct. 23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ:VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrin